master

1
Novel Restorative Therapy for Neurodegenerative
Diseases Cognosci, Inc. at 2009 Life Sciences
Venture Forum
2
Neurodegenerative DiseasesUnmet Medical Need

• Alzheimers Disease
• Progressive loss of cognitive function
• 5 million patients in US, 20-30 million world
  wide
• Economic impact 4 B drug, 128 B total cost
• No effective therapies to stop progression
• Multiple Sclerosis
• Progressive loss of motor function
• 1 million patients worldwide
• Economic impact 5 B drug
• No restorative therapies

3
Alzheimers Disease Brain Atrophy
NORMAL
ALZHEIMERS
4
COG1410 Reduces Pathology in AD Mice
Tau Tangles
Neuron Loss
Amyloid Plaques
Placebo
COG1410
5
COG Peptides Improve Learning and Memory
2-way ANOVA Interaction p 0.036 Errors
p lt0.001 Trial Block p lt0.001
6
COG Peptides Improve Learning and Memory
2-way ANOVA Interaction p 0.036 Errors
p lt0.001 Trial Block p lt0.001
7
COG Peptides Improve Learning and Memory
2-way ANOVA Interaction p 0.036 Errors
p lt0.001 Trial Block p lt0.001
8
Neuro-Restorative Therapy for MS
9
Cognosci Compounds Promote Remyelination
Starting Slice
Cerebellum Slice Culture
10
COG112 Improves Clinical Motor Function
Model of Primary Progressive Multiple Sclerosis
COG112 Treated
Placebo Treated
Li et al. 2006
11
Neuro-Restorative Activity

• Equals
• Anti-Inflammatory Activity
• Neuro-Protective Activity
• Re-Myelination Activity

Cognosci Compounds are the First To Display
Neuro-Restorative Activity
12
Cognoscis Pipeline
Development Stage
In vitro
In vivo
Preclin.

• Multiple Sclerosis
• Alzheimers Disease
• Traumatic Brain Injury
• Intracerebral Hemorrhage
• Rheumatoid Arthritis
• Leukemia

COG112
COG1410/112
COG1410
IND Filing Q2 10
COG1410
COG133
COG445
13
Intellectual Property
Description Type Phase Suppressing
Method Issued US 7,205,280 Microglia Suppressin
g Composition Issued US 7,319,092 Microglia
of Matter 2nd Generation Composition Exami
nation COG Compounds of Matter US
PCT 3rd Generation Composition Submitted COG
Compounds of Matter Novel Target
Methods Submitted Patent counsel Cooley
Godward Kronish
13
14
Management Team Scientific Advisors

• Mike Vitek, Ph.D.
• Founder, President, CSO
• 20 years experience with Roche, Lederle,
  Wellcome, GSK specializing in chronic
  degenerative diseases
• Dale Christensen, Ph.D.
• VP of Research BD
• 15 years experience in Drug Discovery and
  Development
• Fengqiao Li, Ph.D.
• Principal Research Scientist
• 10 years experience in Research and Discovery

Paul OConnor, M.D. Chair of Neurology, Univ. of
Toronto James Burke, M.D. Duke University,
Director of Clinical Research - Bryan Alzheimer's
Disease Research Center Bruce Trapp, Ph.D.
Cleveland Clinic, Chair of Neuroscience Bill
VanNostrand, Ph.D. Stonybrook Univ. Bruce
Burnett, Ph.D. Director, Regulatory Affairs Duke
Clinical Research Institute
15
Milestones and Goals

• Raised 15 M to date in SBIR funds
• IND enabling safety/toxicology studies for 2
  compounds ongoing now
• Raise 8-10 M Series A Q4 09
• File IND Application Q2 10
• Complete Phase I Clinical Trials Q1 11
• Partner with large pharma for Phase II and III
  clinical trials Q2 11

16
The First Restorative Therapies for
Neurodegenerative Disease

• Dale J. Christensen, Ph.D.
• dchristensen_at_Cognosci.com
• Mobile [phone]